Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SERENITY I: BXCL501 in Agitation Associated With Schizophrenia
NCT04268303Phase 3Completed
- Sponsor
- BioXcel Therapeutics, Inc.
- Start
- Jan 2020
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexmedetomidine in agitation (3 arms), sponsored by BioXcel Therapeutics, Inc. Primary endpoint: Positive and Negative Syndrome Scale- Excited Component Total Score at 2 hours. Started Jan 2020; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
agitation
Beyond the preview
Go deeper on NCT04268303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04268303.